Aerospace Stocks Q4 Earnings: HEICO (NYSE:HEI) Best of the Bunch
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the aerospace industry, including HEICO (NYSE:HEI) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the aerospace industry, including HEICO (NYSE:HEI) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Comcast (NASDAQ:CMCSA) and the best and worst performers in the wireless, cable and satellite industry.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at vertical software stocks, starting with Agilysys (NASDAQ:AGYS).
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the specialty retail industry, including National Vision (NASDAQ:EYE) and its peers.
Even during a down period for the markets, Kratos has gone against the grain, climbing to $28.94. Its shares have yielded a 15.4% return over the last six months, beating the S&P 500 by 26%. This run-up might have investors contemplating their next move.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the online marketplace stocks, including Cars.com (NYSE:CARS) and its peers.
West Pharmaceutical Services has gotten torched over the last six months - since October 2024, its stock price has dropped 29.3% to $202.47 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Energizer trades at $27.31 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 13.4% while the S&P 500 is down 10.5%. This may have investors wondering how to approach the situation.
Shareholders of Texas Instruments would probably like to forget the past six months even happened. The stock dropped 22.9% and now trades at $156. This might have investors contemplating their next move.
What a brutal six months it’s been for Medifast. The stock has dropped 29.3% and now trades at $13.05, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.